- Home
- IBRX vs EMN Comparison
IBRX vs EMN Comparison
Compare IBRX & EMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBRX | EMN |
|---|---|---|
| Founded | 2014 | 1920 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 8.0B |
| IPO Year | 2015 | 1996 |
Fundamental Metrics
Financial Performance| Metric | IBRX | EMN |
|---|---|---|
| Price | $7.26 | $75.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | $12.57 | ★ $79.00 |
| AVG Volume (30 Days) | ★ 22.2M | 1.5M |
| Earning Date | 05-11-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 4.48% |
| EPS Growth | ★ 38.71 | N/A |
| EPS | N/A | ★ 4.10 |
| Revenue | $113,288,000.00 | ★ $8,752,000,000.00 |
| Revenue This Year | $88.59 | $1.98 |
| Revenue Next Year | $131.15 | $3.39 |
| P/E Ratio | ★ N/A | $18.34 |
| Revenue Growth | ★ 668.31 | N/A |
| 52 Week Low | $1.83 | $56.11 |
| 52 Week High | $12.43 | $83.47 |
Technical Indicators
Market Signals| Indicator | IBRX | EMN |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 57.39 |
| Support Level | $5.89 | $74.55 |
| Resistance Level | $8.28 | $82.13 |
| Average True Range (ATR) | 0.94 | 2.44 |
| MACD | -0.21 | 0.86 |
| Stochastic Oscillator | 25.33 | 79.51 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
About EMN Eastman Chemical Company
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.